These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 22111618)

  • 1. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.
    Wulff H; Castle NA
    Expert Rev Clin Pharmacol; 2010 May; 3(3):385-96. PubMed ID: 22111618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.
    Lam J; Wulff H
    Drug Dev Res; 2011 Nov; 72(7):573-584. PubMed ID: 22241939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intermediate-conductance Ca2+ -activated K+ channel (KCa3.1) in vascular disease.
    Tharp DL; Bowles DK
    Cardiovasc Hematol Agents Med Chem; 2009 Jan; 7(1):1-11. PubMed ID: 19149539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease.
    Köhler R; Kaistha BP; Wulff H
    Expert Opin Ther Targets; 2010 Feb; 14(2):143-55. PubMed ID: 20055714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.
    Wulff H; Kolski-Andreaco A; Sankaranarayanan A; Sabatier JM; Shakkottai V
    Curr Med Chem; 2007; 14(13):1437-57. PubMed ID: 17584055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.
    Brown BM; Pressley B; Wulff H
    Curr Neuropharmacol; 2018; 16(5):618-626. PubMed ID: 28676010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial Ca+-activated K+ channels in normal and impaired EDHF-dilator responses--relevance to cardiovascular pathologies and drug discovery.
    Grgic I; Kaistha BP; Hoyer J; Köhler R
    Br J Pharmacol; 2009 Jun; 157(4):509-26. PubMed ID: 19302590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical regulation of atherosclerosis by the KCa3.1 channel and the retargeting of this therapeutic target in in-stent neoatherosclerosis.
    Zhu YR; Jiang XX; Zhang DM
    J Mol Med (Berl); 2019 Sep; 97(9):1219-1229. PubMed ID: 31254004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium-dependent potassium channels control proliferation of cardiac progenitor cells and bone marrow-derived mesenchymal stem cells.
    Vigneault P; Naud P; Qi X; Xiao J; Villeneuve L; Davis DR; Nattel S
    J Physiol; 2018 Jun; 596(12):2359-2379. PubMed ID: 29574723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis.
    Tharp DL; Wamhoff BR; Wulff H; Raman G; Cheong A; Bowles DK
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1084-9. PubMed ID: 18309114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ca
    Roach KM; Bradding P
    Br J Pharmacol; 2020 Mar; 177(5):1003-1024. PubMed ID: 31758702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional KCa3.1 K+ channels are required for human fibrocyte migration.
    Cruse G; Singh SR; Duffy SM; Doe C; Saunders R; Brightling CE; Bradding P
    J Allergy Clin Immunol; 2011 Dec; 128(6):1303-1309.e2. PubMed ID: 21872912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ca
    Ohya S; Kito H
    Biol Pharm Bull; 2018; 41(8):1158-1163. PubMed ID: 30068864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inhibition of KCa3.1 channel attenuates airway inflammation and remodeling in allergic asthma.
    Yu ZH; Xu JR; Wang YX; Xu GN; Xu ZP; Yang K; Wu DZ; Cui YY; Chen HZ
    Am J Respir Cell Mol Biol; 2013 Jun; 48(6):685-93. PubMed ID: 23492185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels.
    Grgic I; Kiss E; Kaistha BP; Busch C; Kloss M; Sautter J; Müller A; Kaistha A; Schmidt C; Raman G; Wulff H; Strutz F; Gröne HJ; Köhler R; Hoyer J
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14518-23. PubMed ID: 19706538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KCa3.1/IK1 Channel Regulation by cGMP-Dependent Protein Kinase (PKG) via Reactive Oxygen Species and CaMKII in Microglia: An Immune Modulating Feedback System?
    Ferreira R; Wong R; Schlichter LC
    Front Immunol; 2015; 6():153. PubMed ID: 25904916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The KCa3.1 blocker TRAM-34 inhibits proliferation of fibroblasts in paraquat-induced pulmonary fibrosis.
    Xie H; Lu J; Zhu Y; Meng X; Wang R
    Toxicol Lett; 2018 Oct; 295():408-415. PubMed ID: 30036685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KCa3.1 Ca2+ activated K+ channels regulate human airway smooth muscle proliferation.
    Shepherd MC; Duffy SM; Harris T; Cruse G; Schuliga M; Brightling CE; Neylon CB; Bradding P; Stewart AG
    Am J Respir Cell Mol Biol; 2007 Nov; 37(5):525-31. PubMed ID: 17585114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional KCa3.1 K+ channels are required for human lung mast cell migration.
    Cruse G; Duffy SM; Brightling CE; Bradding P
    Thorax; 2006 Oct; 61(10):880-5. PubMed ID: 16809411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K⁺-channel inhibition reduces portal perfusion pressure in fibrotic rats and fibrosis associated characteristics of hepatic stellate cells.
    Freise C; Heldwein S; Erben U; Hoyer J; Köhler R; Jöhrens K; Patsenker E; Ruehl M; Seehofer D; Stickel F; Somasundaram R
    Liver Int; 2015 Apr; 35(4):1244-52. PubMed ID: 25212242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.